Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Ana Gibertoni Cruz

Ana Gibertoni Cruz

Ana Gibertoni Cruz

DPhil Student

  • Infectious Disease Registrar and Clinical Research Fellow, Moderinising Medical Microbiology (Nuffield Department of Medicine)

Ana joined the Health Economics Research Centre in 2018 where she will conduct health economic analyses to understand how best to deploy whole genome sequencing (WGS) technology for the diagnostics of Infectious Diseases (ID) in low- and middle-income countries. Recent developments in the field, including tuberculosis (TB) WGS becoming routine in England (and other developed countries following suit) and WHO’s assessment on the use of the technology to help control the TB pandemic, have led Ana to conceive a research project with a significant translational potential: Challenges and strategies in implementing genomic diagnostics for infectious diseases in low and middle-income countries: a health economic evaluation.

Ana qualified as an ID physician in Brazil in 2009 (UNICAMP) and, after being awarded a master’s in public health in 2010 (Harvard), she chose to gain some experience of global public health by working with WHO and the International Committee of the Red Cross. 

Prior to starting her DPhil, Ana had been working in the UK since 2012 as an ID registrar and clinical research fellow with Comprehensive Resistance Prediction for Tuberculosis: an International Consortium (, a project whose aim is to unveil the complete genetic basis for antimicrobial resistance in TB by analysing dozens of thousands of genomes of strains from all over the world.